Landmark Wealth Management (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Landmark Wealth Management (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$503K	Buy	+16,700	New	+$537K	0.13%	110

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Landmark Wealth Management (New York)'s TEVA Position: Q1 2026 in Review

Landmark Wealth Management (New York) opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 16,700 shares worth $503K. The stake represents 0.13% of the portfolio and ranks #110 among its holdings.

651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Landmark Wealth Management (New York) held 16,700 shares of Teva Pharmaceuticals worth $503K as of Q1 2026.
Teva Pharmaceuticals was a new Landmark Wealth Management (New York) position in Q1 2026.
Teva Pharmaceuticals made up 0.13% of Landmark Wealth Management (New York)'s portfolio in Q1 2026, its #110 holding.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Landmark Wealth Management (New York)'s 13F filing for Q1 2026, filed 29 Apr 2026.